BACKGROUND: Recurrent head and neck malignancies are therapeutically challenging. Brachytherapy is a retreatment alternative to external-beam radiation therapy (EBRT). METHODS: Patients receiving brachytherapy during 1987-2004 for recurrent head and neck cancer were identified. Tumor and treatment characteristics and toxicities were recorded. Progression-free survival (PFS) and overall survival (OS) estimates were generated. The influence of prognostic factors was determined. RESULTS: Eighty-two patients were analyzable. Analysis was limited to patients who had brachytherapy for a first recurrence (n = 45). Brachytherapy (> or = 55 Gy) was a monotherapy in 22 of 45 patients. As part of their salvage brachytherapy treatments, 14 patients also underwent surgery; 3 patients also underwent EBRT; and 6 patients underwent surgery, EBRT, and brachytherapy. Retreatment morbidity included acute toxicity (n = 7) and late toxicity (n = 18). Median PFS was 15 months, and locoregional control rates at 1 and 2 years were 50% and 37%, respectively. Time to progression differed by site of the primary tumor (p = .10). Median OS was 16 months, and OS at 2 and 5 years was 33% and 11%, respectively. CONCLUSIONS: Brachytherapy for recurrent head and neck cancer has an acceptable toxicity profile and is viable alternative to EBRT. Further optimization of the best sites and doses for neck brachytherapy is required. (c) 2006 Wiley Periodicals, Inc.
BACKGROUND: Recurrent head and neck malignancies are therapeutically challenging. Brachytherapy is a retreatment alternative to external-beam radiation therapy (EBRT). METHODS:Patients receiving brachytherapy during 1987-2004 for recurrent head and neck cancer were identified. Tumor and treatment characteristics and toxicities were recorded. Progression-free survival (PFS) and overall survival (OS) estimates were generated. The influence of prognostic factors was determined. RESULTS: Eighty-two patients were analyzable. Analysis was limited to patients who had brachytherapy for a first recurrence (n = 45). Brachytherapy (> or = 55 Gy) was a monotherapy in 22 of 45 patients. As part of their salvage brachytherapy treatments, 14 patients also underwent surgery; 3 patients also underwent EBRT; and 6 patients underwent surgery, EBRT, and brachytherapy. Retreatment morbidity included acute toxicity (n = 7) and late toxicity (n = 18). Median PFS was 15 months, and locoregional control rates at 1 and 2 years were 50% and 37%, respectively. Time to progression differed by site of the primary tumor (p = .10). Median OS was 16 months, and OS at 2 and 5 years was 33% and 11%, respectively. CONCLUSIONS: Brachytherapy for recurrent head and neck cancer has an acceptable toxicity profile and is viable alternative to EBRT. Further optimization of the best sites and doses for neck brachytherapy is required. (c) 2006 Wiley Periodicals, Inc.
Authors: Peter W Henderson; David I Kutler; Bhupesh Parashar; David M Otterburn; Marc A Cohen; Jason A Spector Journal: J Contemp Brachytherapy Date: 2016-08-29
Authors: Nayel Khan; Mark Clemens; Jun Liu; Adam S Garden; Anne Lawyer; Randal Weber; G Brandon Gunn; William H Morrison; Michael E Kupferman Journal: Cancers Head Neck Date: 2019-07-22
Authors: Julianna Rodin; Voichita Bar-Ad; David Cognetti; Joseph Curry; Jennifer Johnson; Chad Zender; Laura Doyle; David Kutler; Benjamin Leiby; William Keane; Adam Luginbuhl Journal: J Contemp Brachytherapy Date: 2018-10-31
Authors: William Breen; Jacqueline Kelly; Henry S Park; Yung Son; Clarence Sasaki; Lynn Wilson; Roy Decker; Zain A Husain Journal: Cureus Date: 2018-04-22
Authors: Voichita Bar-Ad; Emily Hubley; Adam Luginbuhl; David Cognetti; Joseph Curry; Amy S Harrison; Jennifer M Johnson; James Keller; Cheng Peng; David To; Laura Doyle Journal: J Contemp Brachytherapy Date: 2019-06-28
Authors: Michael Kharouta; Chad Zender; Tarun Podder; Rod Rezaee; Pierre Lavertu; Nicole Fowler; Jason Thuener; Shawn Li; Kate Clancy; Zhengzheng Xu; Min Yao Journal: Front Oncol Date: 2021-03-18 Impact factor: 6.244
Authors: Adam Luginbuhl; Alyssa Calder; David Kutler; Chad Zender; Trisha Wise-Draper; Jena Patel; Michael Cheng; Vidhya Karivedu; Tingting Zhan; Bhupesh Parashar; Shuchi Gulati; Min Yao; Pierre Lavertu; Vinita Takiar; Alice Tang; Jennifer Johnson; William Keane; Joseph Curry; David Cognetti; Voichita Bar-Ad Journal: Front Oncol Date: 2021-11-26 Impact factor: 6.244
Authors: Anthony Pham; Shruthi Arora; A Gabriella Wernicke; David I Kutler; Marc Cohen; William Kuhel; Samuel Trichter; Dattatreyudu Nori; Silvia C Formenti; Bhupesh Parashar Journal: J Contemp Brachytherapy Date: 2015-12-30